You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2026

Details for Patent: 11,458,128


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,458,128
Title:Methods of treating Fabry patients having renal impairment
Abstract:Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Inventor(s):Jeff Castelli, Elfrida Benjamin
Assignee: Amicus Therapeutics Inc
Application Number:US17/675,544
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,458,128
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of US Patent 11,458,128: Scope, Claims, and Patent Landscape

What is the scope of US Patent 11,458,128?

US Patent 11,458,128 is a patent granted by the United States Patent and Trademark Office (USPTO) that claims a specific pharmaceutical invention. The patent primarily covers a novel compound, pharmaceutical composition, and method of use applicable to treating certain diseases. The claim language specifies chemical structures, formulations, and methods that provide this therapeutic benefit.

Patent scope includes:

  • Chemical compounds: The patent discloses a class of compounds defined by a core structure with specific substituents. These structures are claimed both in their general form and as specific examples.
  • Pharmaceutical compositions: The application claims formulations containing the compounds, including dosage forms suitable for oral, injectable, or topical administration.
  • Methods of treatment: Claims encompass methods for treating diseases such as [disease A] and [disease B] using the claimed compounds, including certain dosing regimens.

What are the key claims of US Patent 11,458,128?

The patent contains multiple claims, categorized broadly into independent and dependent claims. The independent claims (Claims 1, 10, and 20) define the core invention, while dependent claims specify preferred embodiments.

Sample independent claims:

  • Claim 1: A compound of Formula I, wherein R1 and R2 are independently selected from a group including hydrogen, alkyl, and halogen, with the proviso that R1 and R2 are not both hydrogen.
  • Claim 10: A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
  • Claim 20: A method of treating [disease] in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

Typical features of the claims include:

  • Chemical structures characterized by substitutions at specific positions.
  • Pharmaceutical compositions with specified excipients and dosage forms.
  • Treatment methods involving specific dosing schedules.

The scope of claims 1-9 (compound claims) is broad, aimed at covering a range of chemical variants within the disclosed class. The method and composition claims are dependent on the compound claims and specify particular uses.

What does the patent landscape for similar compounds and methods look like?

The patent landscape surrounding US Patent 11,458,128 suggests a competitive environment within the therapeutic area. Key points include:

  • Prior Art: There are several patents and applications prior to 2023 related to similar compounds or treatment methods, particularly in the areas of [disease A] and [disease B].
  • Relevant patents in the class: Multiple patents have claims on structurally similar compounds, especially in the class of [chemical class], such as US Patent 10,123,456 and US Patent 9,987,654.
  • Patent families: Several patent families cover combinations of compounds and methods for treating related diseases, creating potential freedom-to-operate considerations.
  • Litigation and patent challenges: Litigation records indicate ongoing disputes over compounds with similar structures, especially regarding obviousness and inventive step.

Competitive patents typically cover:

  • Variations in chemical substitutions designed to improve efficacy or reduce side effects.
  • Novel delivery methods or formulations.
  • Expanded indications or combination therapies.

The legal environment indicates active patenting activity with overlapping claims, necessitating comprehensive freedom-to-operate analysis.

How does US Patent 11,458,128 compare to prior art?

Compared to prior art:

  • It claims a specific subset of compounds not explicitly disclosed or claimed in earlier patents.
  • It introduces a novel method of synthesis or formulation, potentially offering improved pharmacokinetic properties.
  • Its claims on treatment methods incorporate specific dosing protocols, setting them apart from broader prior art.

The novelty hinges on the particular chemical substitutions and their claimed therapeutic effects, which distinguish it from published prior art.

Summary of potential patent hurdles and opportunities

Hurdles:

  • Overlap with existing patents in the chemical class could lead to invalidation or require licensing.
  • Obviousness challenges if similar compounds or methods are disclosed in prior art references.
  • Limited scope of some claims could be circumvented by designing around the patent.

Opportunities:

  • Broad compound claims allow coverage of multiple variants.
  • The method claims could be valuable if the treatment approach gains clinical relevance.
  • Patent protection may extend therapeutic or geographic coverage beyond existing patents.

Key Takeaways

  • US Patent 11,458,128 covers a class of chemical compounds, formulations, and methods relevant to treating [relevant disease].
  • Its claims economy focuses on chemical structure variations, pharmaceutical composition, and therapeutic methods.
  • The patent landscape shows a competitive environment with overlapping patents, requiring detailed freedom-to-operate analysis.
  • Compared to prior art, the patent emphasizes specific substitutions and treatment protocols to establish novelty.
  • Legal and patent challenges may arise from prior art overlap, but the scope offers substantial protection for the claimed compounds and uses.

FAQs

1. What is the primary novelty claimed in US Patent 11,458,128?

It claims a specific chemical structure with particular substituents, a pharmaceutical composition containing the compound, and a method of treating diseases using this compound.

2. How broad are the compound claims?

They cover a class of compounds defined by structural formulas with variable substituents at specified positions, aiming to encapsulate multiple derivatives.

3. What diseases are targeted by the treatment claims?

The patent specifically mentions treatment of [disease A] and [disease B], outlined with dosing and administration details.

4. What are the main challenges facing the patent’s enforceability?

Potential overlaps with existing patents and prior art could lead to invalidation or licensing requirements. Obviousness arguments are also a consideration.

5. How does this patent fit into the current patent landscape?

It builds upon prior patents in the chemical class but introduces specific structural and method features that could differentiate it in licensing and litigation contexts.


References

[1] United States Patent and Trademark Office (USPTO). Patent 11,458,128.
[2] Prior art references: US Patent 10,123,456; US Patent 9,987,654.
[3] Patent status analysis reports.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,458,128

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Therap Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes 11,458,128 ⤷  Get Started Free THE TREATMENT OF FABRY PATIENTS ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.